MAP2K7 and acral lentiginous melanoma: BRAF (vemurafenib, dabrafenib, encorafenib) and MEK (trametinib, cobimetinib) inhibitors have been well studied for the treatment of cutaneous melanomas, with limited data for the treatment of acral melanoma (NUM specifically) [65].